39811-03-5

Basic information

• Product Name: 5,6-Dichloro-2-(chloromethyl)-1H-benzimidazole
• Synonyms: 5,6-Dichloro-2-(chloromethyl)-1H-benzimidazole
• CAS NO: 39811-03-5
• Molecular Formula: C₈H₅Cl₃N₂
• Molecular Weight: 235.4977
• Mol File: 39811-03-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 437.2°C at 760 mmHg
• Flash Point: 250.8°C
• Appearance: /
• Density: 1.605g/cm³
• Vapor Pressure: 1.95E-07mmHg at 25°C
• Refractive Index: 1.691
• CAS DataBase Reference: 5,6-Dichloro-2-(chloromethyl)-1H-benzimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-Dichloro-2-(chloromethyl)-1H-benzimidazole(39811-03-5)
• EPA Substance Registry System: 5,6-Dichloro-2-(chloromethyl)-1H-benzimidazole(39811-03-5)

Safety Data

• Hazardous Substances Data: 39811-03-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H5Cl3N2/c9-3-8-12-6-1-4(10)5(11)2-7(6)13-8/h1-2H,3H2,(H,12,13)

Upstream product

• 5348-42-5 4,5-Dichloro-1,2-phenylenediamine 
• 79-11-8 chloroacetic acid 
• 79-04-9 chloroacetyl chloride 
• 6306-39-4 1,2-dichloro-4,5-dinitrobenzene 
• 6478-80-4 5,6-dichloro-2-hydroxymethyl-1H-benzimidazole 

Downstream Products

• 1036383-52-4 4-(5,6-dichloro-1H-benzoimidazol-2-ylmethoxy)-2-fluoro-5-methoxy-benzaldehyde 

Relevant articles and documents

PYRAZOLOTRIAZINES

The present invention provides compounds of general formula (I), in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.

2-Substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

The present invention discloses compounds of formula I wherein Ar, Y, m, n, R1 and R4 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

Benzimidazoles and isosteric compounds as potent and selective factor Xa inhibitors.

Benzimidazoles and their isosteric compounds as factor Xa inhibitors are discussed.